

**DEBORAH C. MARSHALL**  
**08/22/2023**

**EDUCATION**

Undergraduate/Post-Baccalaureate

08/2004                    B.A. in Ethnic Studies, University of California, Berkeley (Berkeley, CA)  
12/2009                    Post-baccalaureate Pre-medical Certificate, University of Southern California (Los Angeles, CA)

Graduate

09/2015                    M.A.S., Clinical Research, University of California, San Diego (La Jolla, CA)

Undergraduate Medical

06/2016                    M.D., University of California, San Diego (La Jolla, CA)

Graduate Medical

06/2016-06/2017            Transitional Year Intern, Memorial Sloan Kettering Cancer Center (New York, NY)  
07/2017-06/2018            Resident, Radiation Oncology, University of California, San Diego (La Jolla, CA)  
07/2018-06/2021            Resident, Radiation Oncology, Mount Sinai Hospital (New York, NY)  
01/2020-06/2021            Chief Resident, Radiation Oncology, Mount Sinai Hospital (New York, NY)

Research Fellowships

07/2014-06/2015            NIH TL-1 Pre-Doctoral Research Fellow  
                                  UCSD School of Medicine (La Jolla, CA), Primary Mentor: Hattangadi-Gluth  
07/2019-06/2021            ABR B. Leonard Holman Pathway, Research Resident  
                                  Radiation Oncology, Icahn School of Medicine at Mount Sinai (New York, NY)  
                                  Primary Mentors: Wisnivesky/Sigel  
07/2019-06/2021            NIH/NCI T32 National Research Service Award, Post-Doctoral Research Fellow  
                                  Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai (New York, NY)  
                                  Primary Mentors: Sigel

**LICENSURE**

2017-present                Medical Board of California, Physician and Surgeon A (A152703)  
2021-present                New York State, Medicine and Surgery License (312506)  
2022                        Diplomate, American Board of Radiology, Radiation Oncology

### **PROFESSIONAL APPOINTMENTS**

04/2003-06/2007	Trainer and Legal Assistant, Berry, Appleman & Leiden LLP (San Francisco, CA)
08/2006-04/2011	Programmer/Analyst, Ettner Lab, UCLA Department of Medicine, Division of General Internal Medicine and Health Services Research (Los Angeles, CA)
02/2010-08/2011	Research Associate, Metzger Biomechanics Lab, Cedars-Sinai Medical Center (Los Angeles, CA)
08/2021-present	Assistant Professor (Tenure Track), Department of Radiation Oncology, Department of Population Health Science and Policy, and the Blavatnik Family Women's Health Research Institute, Icahn School of Medicine at Mount Sinai (New York, NY)
11/2022-present	Didactic (Teaching) Faculty, Graduate School of Biomedical Sciences of the Icahn School of Medicine at Mount Sinai, Clinical Research and Cancer Biology (CAB)

### **HONORS/AWARDS**

2003	Northern California and Pacific Coast Regional All-Star Teams, USA Rugby
2010	Volunteer of the Year Award, Shriner's Hospital for Children
2015	Leksell Radiosurgery Award, 83rd American Association of Neurosurgeons (AANS) Annual Scientific Meeting
2015	Conquer Cancer Foundation of ASCO Merit Award, 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
2015	UCSD Physician Assessment and Clinical Education (PACE) Program Underserved Community Grant for International Experiences, Bangalore and Thiruvananthapuram, India
2016	Jean & Elliot Marvell Award in Radiation Oncology, Univ. of California San Diego School of Medicine
2016	Glasgow-Rubin Citation for Academic Achievement, Univ. of California San Diego School of Medicine
2018	American Society for Radiation Oncology (ASTRO) Advocacy Day Travel Grant
2019	Conquer Cancer Foundation of ASCO Merit Award, 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
2019	CARROS Resident Travel Grant, American College of Radiology (ACR), Washington DC
2019	Resident Seed Grant, American College of Radiation Oncology (ACRO)
2020	American Association for Women in Radiology ASTRO MIT Outstanding Presentation Award

### **OTHER PROFESSIONAL ROLES**

**MEMBERSHIPS**

2020 Alpha Omega Alpha (AOA) Honor Society

**COMMITTEE SERVICE**

2014-2015 Admissions Committee, University of California, San Diego School of Medicine

2018- Economics Committee, American College of Radiology

2018-2020 Quality Assurance Committee, Mount Sinai Hospital, Department of Radiation Oncology

2019-2020 Medical Board, Mount Sinai Hospital

2022-present Research and Grants Committee Member, International Society for the Study of Women's Sexual Health

2022-present NRG Oncology, Cancer Prevention and Control Committee Member

2023-present ISSM International Consultation on Sexual Medicine, Sexual function in Chronic Illness and Cancer Committee Member

**PEER REVIEW SERVICE**

The BMJ, JAMA, IJROBP, Blood Cancer Journal.

**RESEARCH PROFILE**

I have a successful well-funded research track record with >\$2 million in research funding as Principal Investigator and a productive record of collaborations and publishing high-impact research, including over 40 articles (15 as first author, 4 as senior author) in peer-reviewed journals (including first-authored articles in JAMA, JAMA Oncology, CA: A Cancer Journal for Clinicians, and JNCI). My overall research goals include elucidating innovative patient-centered approaches to optimize cancer therapy and reduce radiotherapy-associated toxicities in priority populations (including women, sexual/gender minority patients, and persons living with HIV) in addition to generating fundamental health policy data drawing critical attention to the potential impacts of transparency in medicine and oncology.

While completing post-doctoral training, I was Principal Investigator on mentored grants from the Patty Brisben Foundation, NRG Oncology, and the Conquer Cancer Foundation of ASCO, leading a multidisciplinary team to develop novel approaches to defining the functional anatomy involved in female sexual toxicity after radiotherapy – re-centering the paradigm of female sexual health in cancer survivorship to include pleasurable sensation. To date, my team has developed the first-ever description of the female erectile tissues (namely, the clitoris or bulbocavernosus) for radiotherapy planning, and we have proposed a novel approach to sparing these tissues with advanced radiotherapy techniques. Now, we are analyzing patient- and clinician-reported outcomes to establish dose-volume effects of radiotherapy on sexual organs, by using advanced statistical methods to analyze prospective data.

My current NIH Early Independence Award-funded research program centers on integrating a paradigm-shifting precise understanding of female functional sexual anatomy, so as to develop novel dosimetric predictors and advance understanding of microbiome and quantitative imaging biomarkers. We will then combine these insights to guide the development of evidence-based engineering advances and interventions to preserve erectile or mucosal function and alter the microbiome landscape. We are also investigating novel interventions in collaboration with biomedical engineering, including ultra high-field imaging, hydrogel technologies to prevent vaginal stenosis and dose-limiting toxicities during brachytherapy and soft bioelectronics to restore sensation. My research program will provide multidisciplinary leadership on this important area of survivorship, leveraging strengths in focusing on priority populations who experience a disproportionate burden of cancer and will have unique needs related to sexual health, including racial and ethnic minorities, women, and sexual/gender minority patients. This research urgently addresses multiple underrepresented areas of scientific discovery.

### **CLINICAL PROFILE**

My dedication to providing excellent and compassionate clinical care is central to all my professional pursuits. I have clinical experience across disease sites and treatment modalities including external beam therapies, proton therapy and brachytherapy. I am also clinically interested in leveraging and developing advanced imaging and technologies to improve toxicity outcomes, as referenced in my research profile above. My clinical and translational research in toxicity and its mitigation can enhance clinical care and improve outcomes broadly, translating to a clinical focus on multiple disease sites. I am committed to using a collaborative team-based management approach to providing excellent clinical care. Much of this leadership was recently recognized in my election as a house-staff member of the Alpha Omega Alpha Medical Honor Society. I aim to build a strong clinical practice in treating young adults, as well as those with breast and pelvic cancers with proton radiotherapy, integrating novel advances in genomic and epigenetic risk stratification and employing emerging technologies to improve patient oncologic and quality of life outcomes. I also aim to build a collaborative multidisciplinary clinical program establishing this practice as a destination for cancer care by optimizing sexual health in cancer pre- and survivorship for female and LGBT/gender diverse patients that will synergize with research leadership in this important and growing area.

### **OVERALL IMPACT**

My clinical and translational research elucidating innovative patient-centered approaches to optimizing cancer therapy and reducing radiotherapy-associated sexual toxicities in priority populations has attracted national recognition as evidenced by strong foundation and cooperative group support. Continued success in my planned research will provide a unique and high-profile niche in leadership of a new and important research domain in female sexual toxicities in cancer survivors and enable my team to attract substantial future external research funding, high visibility, high-quality future trainees, and a rich diversity of cancer patients who are radiotherapy candidates, who seek treatment and may also be willing to enroll in my planned research studies. I aim to provide national and international multidisciplinary leadership on the important clinical area of toxicity and survivorship in priority populations and catalyze strategic partnerships between researchers in women's health and biomedical engineering and imaging to advance research development in this high priority area.

### **DIVERSITY AND INCLUSION IMPACT**

My research has focused on cancer prevention and control in priority populations which has taken an inclusive approach to addressing and transforming our knowledge of under-represented scientific topics, including female and LGBT sexual health in diverse populations of cancer survivors as well as oncologic outcomes in persons living with HIV. I will also continue my commitment to intentionally building a diverse oncology workforce and incorporating an inclusive, patient-centered approach to research and education

with involvement of diverse communities of patients at multiple levels to reshape clinical care in a way that empowers all of our patients and all of us.

### **MENTORING PROFILE**

I am actively engaged in advising and mentoring diverse students and residents in clinical radiation oncology and clinical research, in addition to training research scholars in clinical and translational research. My trainees have presented their research at national meetings and obtained national and international grants and awards for their research.

### **GRANTS, CONTRACTS, FOUNDATION SUPPORT**

#### **CURRENT GRANTS**

<u>Funding Source, Project Title &amp; Number</u>	<u>Role in Project</u>	<u>Dates</u>	<u>Direct Costs</u>
National Institutes of Health/Office of the Director Early Independence Award (DP5OD031876) High-Risk, High-Reward Research Program Title: Novel functional anatomic and biomarker indices of radiation-induced female sexual toxicities in a multicenter cohort	PI	09/21-08/26	Total: 1,515,683
NIH Loan Repayment Program – Clinical Research (L30CA274758)	Clinical Investigator	07/22-07/24	Total: 100,000

#### **PENDING GRANTS**

<u>Funding Source, Project Title &amp; Number</u>	<u>Role in Project</u>	<u>Dates</u>	<u>Direct Costs</u>
National Institutes of Health/National Cancer Institute (R01CA285342) PI: Sigel/Chiao/Deshmukh Title: Optimizing prostate cancer treatment for people living with HIV	Co-I	07/23-06/28	Total: 4,083,919

#### **PAST GRANTS**

<u>Funding Source, Project Title &amp; Number</u>	<u>Role in Project</u>	<u>Dates</u>	<u>Direct Costs</u>
NIH-NCI/NRG Oncology NCORP PILOT Grant (2UG1CA189867-06) Title: A multidisciplinary approach to re-defining functional anatomic organs at risk for sexual toxicity in women undergoing pelvic radiation	PI	09/19-06/21	Total: 5,000
Patty Brisben Foundation for Women's Sexual Health	PI	07/19-06/20	Total: 44,539

<p>Title: A multidisciplinary approach to re-defining functional anatomic organs at risk for sexual toxicity in women undergoing pelvic radiation</p> <p>Conquer Cancer Foundation of ASCO Young Investigator Award</p> <p>Title: A multidisciplinary approach to re-defining functional anatomic organs at risk for sexual toxicity in women undergoing pelvic radiation</p>	PI	07/20-12/21	Total: 48,750
---	----	-------------	---------------

### **CLINICAL TRIALS PARTICIPATION**

<u>Project</u>	<u>Role in Project</u>	<u>Dates</u>	<u>Award</u>
<p>NCTN/Children's Oncology Group (COG) PI: Levine/Chow Title: Gonadotropin-Releasing Hormone Analogs (GnRHa) and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer (ALTE2131)</p>	NRG Study Champion	07/23-present	Pending

### **TRAINEES**

<u>Name</u>	<u>Level of Trainee</u>	<u>Role in Training &amp; Inclusive Dates</u>	<u>Training Venue</u>	<u>Trainees' Current Status/Employment</u>
Elaine Cha	MD Candidate	Mentor, 2019-2021	Research	Resident Physician (MDACC)
Camille Hardy-Abeloos	MD Candidate	Mentor, 2020	Research	Resident Physician (NYU)
Orly Morgan	MD MPH Candidate	Mentor, 2020-present	Research	MD MPH Candidate (UMiami) ISSWSH Grant Recipient
Ayesha Ali	Resident	Mentor, 2020-present	Research	Resident Physician (Jefferson)
Kristin Hsieh	Resident	Mentor, 2021-present	Research	Resident Physician (ISMMS)
Carlos Rodriguez-Russo	Resident	Mentor, 2021-present	Research	Resident Physician (ISMMS) ARS Travel Award 2023
Lucy Greenwald	MD Candidate	Mentor, 2021-present	Research	MD Candidate (ISMMS)
Margo Downes	MD/MSCR Candidate	Mentor, 2021-present	Research	MD/MSCR Candidate - PORTAL Program, BFWHRI Summer Research Fellow (ISMMS), 2023 ISSWSH Research Grant Recipient, 2023

Daniel Dickstein	Resident	Mentor, 2022-present	Research	Resident Physician (ISMMS) ARS Travel Award, 2023 ASCO Young Investigator Award Recipient, 2023
------------------	----------	----------------------	----------	---

## **TEACHING ACTIVITIES**

<u>Teaching Activity/Topic</u>	<u>Level</u>	<u>Role</u>	<u>Level and Number of Learners Taught, and Venue</u>	<u>Number of hours</u>	<u>Years Taught</u>
InFocus Statistics (survival/regression)	Undergraduate Medical	Group Facilitator	Undergraduate Medical, 10, ISMMS	4 hours/year	2020
PORTAL Journal Club	Undergraduate Medical/Graduate	Presenter	Undergraduate Medical/Graduate, 5, ISMMS	1 hour/year	2020
Guest Lecture	Graduate Medical	Presenter	Graduate Medical, 5, MSKCC	1 hour/year	2020
Guest Lecture	Undergraduate	Instructor	Undergraduate, Therapist Training, Stony Brook/ISMMS	1 hour/year	2022-present
Resident Precepting	Graduate Medical	Attending	Graduate Medical, 10, ISMMS/NYPC	10 months/year	2022-present
InFocus Research Integrity	Undergraduate Medical	Group Facilitator	Undergraduate Medical, 20, ISMMS	4 hours/year	2023
Accelerating Inclusion in Medicine and Healthcare Innovation (AIM-HI) Pipeline Program	Undergraduate	Mentor/Presenter	Undergraduate, 2/8, ISMMS	8 weeks/1 hour per year	2022
Public Health and Racial Justice Program	Secondary	Mentor	Secondary, 1, ISMMS	1 hour/year	2023

## **PUBLICATIONS**

H Index: 16 (Google Scholar; 5/8/23)

### **Peer Reviewed Original Contributions**

1. Bae HW, Zhao L, Kanim LEA, Wong P, Marshall DC, Delamarter RB. Bone marrow aspirate enhances the performance of rhBMP-2 in spinal fusion: A rodent model. **J Bone Joint Surg Am.** 2013 Feb; 20;95(4):338-347.

2. Marshall DC, Punglia RS, Fox D, Recht A, and Hattangadi-Gluth JA. Medical malpractice in radiation oncology: A population-based study 1985-2012. **Int J Radiat Oncol Biol Phys.** 2015 Oct 1;93(2):241-50. doi: 10.1016/j.ijrobp.2015.05.040.
3. Barnes A, Moore AA, Xu H, Mirkin M, Marshall DC, Ang A, Tallen L, Ettner SL. The effect of a patient-provider educational intervention to reduce at-risk drinking on changes in health and health-related quality of life among older adults: The Project SHARE study. **J Subst Abuse Treat.** 2016 Jan;60:14-20.
4. Marcus LP, Marshall DC, Hirshman BR, McCutcheon BA, Gonda DD, Koiso T, Hattangadi-Gluth JA, Carter BS, Yamamoto M, Chen CC. Cumulative Intracranial Tumor Volume (CITV) enhances the prognostic value of the lung-specific Graded Prognostic Assessment (GPA) model. **Neurosurgery.** 2016 Aug;79(2):246-52.
5. Marshall DC, Jackson ME, Hattangadi-Gluth JA. Disclosure of industry payments to physicians: An epidemiologic analysis of early data from the Open Payments program. **Mayo Clin Proc.** 2016 Jan;91(1):84-96.
6. Karunamuni R, Bartsch H, White N, Moiseenko V, Carmona R, Marshall DC, Seibert T, Carrie McDonald CR, Farid N, Krishnan A, Mell L, Brewer J, Dale AM, Hattangadi-Gluth JA. Dose-dependent cortical thinning after partial brain radiation in high-grade glioma. **Int J Radiat Oncol Biol Phys.** 2016 Feb 1;94(2):297-304.
7. Karunamuni RA, Moore KL, Seibert TM, Li N, White NS, Bartsch H, Carmona R, Marshall DC, McDonald CR, Farid N, Krishnan A, Kuperman J, Mell LK, Brewer J, Dale AM, Moiseenko V, Hattangadi-Gluth JA. Radiation sparing of cerebral cortex in brain tumor patients using quantitative neuroimaging. **Radiother Oncol.** 2016 Jan;118(1):29-34.
8. Marshall DC, Marcus LP, Kim TE, McCutcheon BA, Goetsch SJ, Koiso T, Alksne JF, Ott K, Carter BS, Hattangadi-Gluth JA, Yamamoto M, Chen CC. Management patterns of patients with cerebral metastases who underwent multiple stereotactic radiosurgeries. **Neurooncol.** 2016 May;128(1):119-128.
9. Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA. Distribution and Patterns of Industry-Related Payments to Oncologists in 2014. **J Natl Cancer Inst.** 2016 Dec;108(12).
10. Seibert TM, White NS, Kim GY, Moiseenko V, McDonald CR, Farid N, Bartsch H, Kuperman J, Karunamuni R, Marshall DC, Holland D, Sanghvi P, Simpson DR, Mundt AJ, Dale AM, Hattangadi-Gluth JA. Distortion inherent to magnetic resonance imaging can lead to geometric miss in radiosurgery planning. **Pract Radiat Oncol.** 2016 Nov - Dec;6(6):e319-e328.
11. Connor M, Karunamuni R, McDonald C, White N, Pettersson N, Moiseenko V, Seibert T, Marshall DC, Cervino L, Bartsch H, Kuperman J, Murzin V, Krishnan A, Farid N, Dale A, Hattangadi-Gluth J. Dose-dependent white matter damage after brain radiotherapy. **Radiother Oncol.** 2016 Nov;121(2):209-216.
12. Connor MJ, Marshall DC, Moiseenko V, Moore K, Cervino L, Atwood T, Sanghvi P, Mundt AJ, Pawlicki T, Recht A, Hattangadi-Gluth JA. Adverse Events Involving Radiation Oncology Medical Devices: Comprehensive Analysis of US Food and Drug Administration Data, 1991 to 2015. **Int J Radiat Oncol Biol Phys.** 2017 Jan 1;97(1):18-26.
13. Marshall DC, Tringale K, Connor M, Punglia R, Recht A, Hattangadi-Gluth J. Nature of Medical Malpractice Claims Against Radiation Oncologists. **Int J Radiat Oncol Biol Phys.** 2017 May 1;98(1):21-30.

14. Connor MJ, Tringale K, Moiseenko V, Marshall DC, Moore K, Cervino L, Atwood T, Brown D, Mundt AJ, Pawlicki T, Recht A, Hattangadi-Gluth JA. Medical Device Recalls in Radiation Oncology: Analysis of US Food and Drug Administration Data, 2002-2015. **Int J Radiat Oncol Biol Phys.** 2017 Jun 1;98(2):438-446.
15. Tringale KR, Marshall DC, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA. Types and distribution of industry payments to US physicians in 2015. **JAMA.** 2017 May 2;317(17):1774-1784.
16. Takayesu JSK, Tringale KR, Marshall DC, Burkeen J, Valasek MA, Hemming A, Atwood T, Simpson D, Hattangadi-Gluth JA. Bullet fragment fiducials in stereotactic body radiotherapy as a bridge to transplant for hepatocellular carcinoma. **Acta Oncol.** 2017 Oct;56(10):1324-1327.
17. Tringale KR, Nguyen T, Bahrami N, Marshall DC, Leyden KM, Karunamuni R, Seibert TM, Kay Gorman M, Connor M, Burkeen J, Piccioni DE, Farid N, Hattangadi-Gluth JA, McDonald CR. Identifying early diffusion imaging biomarkers of regional white matter injury as indicators of executive function decline following brain radiotherapy: A prospective clinical trial in primary brain tumor patients. **Radiother Oncol.** 2019 Mar;132:27-33. PMCID: PMC6400307.
18. Tringale KR, Huynh-Le MP, Salans M, Marshall DC, Shi Y, Hattangadi-Gluth JA. The role of cancer in marijuana and prescription opioid use in the United States: A population-based analysis from 2005 to 2014. **Cancer.** 2019 Jul 1;125(13):2242-2251. PMCID: PMC6810711.
19. Karunamuni R, Tringale KR, Burkeen J, Tibbs MD, Huynh-Le MP, Bahrami N, Marshall DC, Seibert TM, McDonald CR, Hattangadi-Gluth JA. Multi-domain neurocognitive classification of primary brain tumor patients prior to radiotherapy on a prospective clinical trial. **J Neurooncol.** 2020 Jan;146(1):131-138. PMCID: PMC7025809.
20. Marshall DC, Kao D, Bakst RL, Sharma S, Ferrandino R, Rosenzweig K, Wisnivesky J, Sigel K. Prognostic Role of HPV Status in Hypopharyngeal Squamous Cell Carcinoma. **Laryngoscope Investig Otolaryngol.** 2020 Aug 11;5(5):860-867. doi: 10.1002/lio2.443. eCollection 2020 Oct. PMCID: PMC7585257.
21. Tibbs M, Huynh-Le M, Reyes A, Macari AC, Karunamuni R, Tringale K, Burkeen J, Marshall DC, Xu R, McDonald C\*, Hattangadi-Gluth J\*. Longitudinal Analysis of Depression and Anxiety Symptoms as Independent Predictors of Neurocognitive Function in Primary Brain Tumor Patients. **Int J Radiat Oncol Biol Phys.** 2020 Dec 1;108(5):1229-1239. PMCID: PMC7680441.
22. Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S. Trends in industry payments to physicians in the United States from 2014 to 2018. **JAMA.** 2020 Nov 3;324(17):1785-1788. PMCID: PMC7610185.
23. Marshall DC, Tarras ES, Yom S, Rosenzweig K, Hattangadi-Gluth J, Murphy J, Korenstein D, Chimonas S. Trends in industry payments to radiation oncologists and other physicians in the United States from 2014 to 2018. **Int J Radiat Oncol Biol Phys.** 2021 Jan 1;109(1):15-25. PMCID: PMC7736120.
24. Tarras ES\*, Marshall DC\*, Rosenzweig K, Korenstein D, Chimonas S. Trends in industry payments to medical oncologists in the United States from 2014 to 2019. **JAMA Oncol.** 2021 Mar 1;7(3):440-444. PMCID: PMC7774046.
25. Marshall DC, Ghiassi-Nejad Z, Powers A, Argiriadi P, Reidenberg J, Ru M, Dumane V, Buckstein M, Goodman K, Schnur J, Rosenstein B. A first description and contouring guideline for the bulboclitoris, a novel female sexual anatomic organ in radiotherapy, and organ-sparing feasibility study. **Br J Radiol.** 2021 Aug 1;94(1124):20201139. PMCID: PMC8764912.
26. Salans MA, Yip A, Burkeen J, Liu KX, Lee E, Tonya Pan-Weisz T, Marshall D, McDuff SGR, Sharifzadeh Y, Dalia Y, Sanghvi P, Simpson D, Xu R, McDonald C, Hattangadi-Gluth J. Prospective longitudinal

assessment of health-related quality of life in patients with brain metastases undergoing radiation therapy. **Am J Clinical Oncology**. 2021 Oct 1;44(10):536-543. PMCID: PMC8458239.

27. Marshall DC, Aldridge M, Dharmarajan K. Retrospective analysis of characteristics associated with higher-value radiotherapy episodes of care for bone metastases in Medicare fee-for-service beneficiaries. **BMJ Open**. 2021 Oct 19;11(10):e049009. PMCID: PMC8527129.
28. Liu BY, Rehmani S, Kale MS, Marshall DC, Rosenzweig KE, Kong CY, Wisnivesky J, Sigel K. Risk of Cardiovascular Toxicity According to Tumor Laterality Among Older Patients With Early Stage Non-small Cell Lung Cancer Treated With Radiation Therapy. **Chest**. 2022 Jun;161(6):1666-1674. doi: 10.1016/j.chest.2021.12.667. Epub 2022 Jan 19. PubMed PMID: 35063448; PubMed Central PMCID: PMC9248076.
29. Bloom JR, Marshall DC, Rodriguez-Russo C, Martin E, Jones J, and Dharmarajan K. Prognostic Disclosure: A Scoping Review on Current Communication Models and their Application in Oncology. **BMJ Supp Pall Care**. In press.
30. Cha E, Mathis NJ, Joshi H, Sharma S, Zinovoy M, Ru M, Cahlon O, Gillespie EF, Marshall DC. Bias in Patient Experience Scores in Radiation Oncology: A Multicenter Retrospective Analysis. **J Am Coll Radiol**. 2022 Apr;19(4):542-551. PMCID: PMC9017791.
31. Marshall DC, Tarras ES, Ali A, Bloom J, Torres MA, Kahn JM. Female erectile tissues and sexual dysfunction after pelvic radiotherapy: A scoping review. **CA Cancer J Clin**. 2022 Jul;72(4):353-359. doi: 10.3322/caac.21726. Epub 2022 Mar 17. Review. PubMed PMID: 35298025; PubMed Central PMCID: PMC9262811.
32. Dickstein DR, Marshall DC. Top, bottom or vers? Creating a more equitable health system for sexual and gender minority patients with prostate cancer. **Nat Rev Urol**. 2022 Jun;19(6):321-322. doi: 10.1038/s41585-022-00600-6. PubMed PMID: 35478032.
33. Kao DD, Ferrandino RM, Marshall DC, Mutetwa T, Miles B, Bauml JM, Sigel KM. Sex-Related Differences in Outcomes for Oropharyngeal Squamous Cell Carcinoma by HPV Status. **Int J Otolaryngol**. 2022;2022:4220434. doi: 10.1155/2022/4220434. eCollection 2022. PubMed PMID: 35546963; PubMed Central PMCID: PMC9085342.
34. Morgan O, Lopez MD, Martinez AJC, Marshall DC, Schnur JB. Systematic Review of Comparisons Between Plastic and Silicone Dilators: Revealing a Knowledge Gap. **Sex Med Rev**. 2022 Oct;10(4):513-519. doi: 10.1016/j.sxmr.2022.06.008. Epub 2022 Aug 25. PMID: 36030181; PMCID: PMC9561033.
35. Marshall DC, Green S, Jones BM, Starrs C, Montgomery GH, Minassian K, Wunder B, Force J, Schnur JB. Trauma-Informed Radiation Therapy: Implementation and Evaluation of a Sensitive Practice Tool for Female Patients Undergoing Radiotherapy for Breast Cancer. **J Am Coll Radiol**. 2022 Sep 17:S1546-1440(22)00701-3. doi: 10.1016/j.jacr.2022.07.011. Epub ahead of print. PMID: 36126825.
36. Kao DD, Ferrandino RM, Bauml JM, Marshall DC, Bakst R, Roof S, Park YA, Bates SE, Sigel KM. Prophylactic Feeding Tube Placement for Squamous Cell Carcinoma of the Head and Neck. **Oral Oncology**. In Press.
37. Tran JH, Mhango G, Park HS, Marshall DC, Rosenzweig KE, Wang Q, Wisnivesky JP, Veluswamy RR. Outcomes Following SBRT vs. IMRT and 3DCRT for Older Patients with Stage IIA Node-Negative Non-Small Cell Lung Cancer > 5 cm. **Clin Lung Cancer**. 2022 Nov 1:S1525-7304(22)00242-X. doi: 10.1016/j.cllc.2022.10.006. Epub ahead of print. PMID: 36443153.
38. Morgan O, Schnur J, Caban-Martinez A, Duenas-Lopez M, Huang M, Portelance L, Elkhadem A, Marshall DC. A Qualitative Analysis of Female Patient Perspectives on Physician Communication

Regarding Sexual Dysfunction Associated with Pelvic Radiotherapy. **The Journal of Sexual Medicine**, 2023. In press.

39. Kao DD, Ferrandino RM, Marshall DC, Roof S, Chai RL, Park YA, Sigel KM. Neutrophil-to-Lymphocyte Ratio as a Predictor of Surgical Outcomes in Head and Neck Cancer. **Head and Neck**. In press.
40. Dickstein D, Edwards C, Lehrer E, Tarras E, Gallito M, Sfakianos J, Galsky M, Stock R, Safer J, Rosser S, Marshall DC. Sexual health and treatment-related sexual dysfunction in sexual and gender minorities with prostate cancer. **Nature Reviews Urology**. In press.
41. Smart AC, Liu KX, Domogauer JD, Rodriguez-Russo C, Jones B, Dickstein DR, Mancias JD, Shiloh Y, Wintner A, Zietman AL, Marshall DC, Dyer MA, Russo AL. Gender-affirming Surgery and Cancer: Considerations for Radiation Oncologists for Pelvic Radiation in Transfeminine Patients. **Int J Radiat Oncol Biol Phys**. In press.
42. Chow R, Hasan S, Choi JI, Fox J, Chhabra AM, Marshall DC, Bakst RL, Simone CB. Effect of Treatment Interruptions on Overall Survival in Patients With Triple Negative Breast Cancer. **J Natl Cancer Inst**. In press.
43. Marshall DC, Carney LM, Hsieh K, Dickstein DR, Downes M, Chaudhari A, McVorran S, Montgomery GH, Schnur JB. Impacts of Trauma History on Cancer-Related Screening, Diagnosis, and Treatment. **The Lancet Oncology**. In press.
44. Duenas Lopez M, Morgan O, Marshall D, Carney L, Caban-Martinez A, Huang M, Portelance L, Schnur J. Cuban American Perspectives on Sexual Dysfunction Following Pelvic Radiotherapy: A Qualitative Study. **Sexuality and Disability**. In press.

#### **Invited Peer Reviewed Contributions**

1. Marshall DC. Letter in Reply to Halperin, 2021. **Int J Radiat Oncol Biol Phys**. 2021 Oct 1;111(2):573-574. doi: 10.1016/j.ijrobp.2021.05.118. PMCID: PMC8830908.
2. Marshall DC, Tarras ES, Chimonas S. Industry Payments to Medical Oncologists-Reply. **JAMA Oncol**. 2021 Jul 1;7(7):1073-1074. PMCID: PMC8830909.

#### **Submitted Publications**

- 1.

#### **Non-Peer Reviewed Publications**

1. Marshall DC, Dharmarajan K. Communication skills for oncology clinicians during COVID-19. Available at <https://www.vitaltalk.org/topics/covid-collaborative-resources/> and <https://ascopost.com/issues/august-10-2020/improving-communication-skills-for-oncology-clinicians-during-the-covid-pandemic/>.

#### **Book Chapters**

1. Ghiassi-Nejad Z, Marshall DC. Abdomen and Pelvis: Symptoms and Toxicities, in Vapiwala, et al.: Palliative Radiation Oncology, 1e.

#### **PRESENTATIONS**

#### **INVITED LECTURES**

1. Marshall DC. Impacts of radiotherapy on sexual function. The Scientific Network on Female Sexual Health and Cancer, November 2021.
2. Marshall DC. Plenary: State of the Art 2: Clitoris Update. International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting 2023. St. Louis, MO, USA.
3. Marshall DC. Education Session: Sexual Health Considerations for Sexual and Gender Minority (SGM) and Non-SGM Patients with a Cancer Diagnosis. ASTRO 2023 Annual Meeting. San Diego CA, USA
4. Marshall DC. Breakout Session: Sexual health after bladder cancer treatment. BCAN Bladder Cancer Think Tank 2023. Washington DC, USA.
5. Marshall DC. Contouring of female sexual organs: which, why and how? 2023 GEC-ESTRO Workshop, Prague CZ, EU.

#### VOLUNTARY ORAL SCIENTIFIC PRESENTATIONS

1. Marshall DC, Kim TE, Goetsch SJ, Alksne JF, Ott K, Hodgens DW, Carter BS, Hattangadi-Gluth JA, and Chen CC. Survival patterns of patients with cerebral metastases after multiple rounds of stereotactic radiosurgery (SRS). 83rd American Academy of Neurological Surgeons (AANS) Annual Scientific Meeting, May 2-6, 2015.
2. Marshall DC, Jackson ME, Hattangadi-Gluth JA. Disclosure of Industry Payments to Oncologists: Early Data from the Open Payments Program. The American Society for Radiation Oncology's (ASTRO) 57<sup>th</sup> Annual Meeting, October 18-21, 2015.
3. Marshall DC, Karunamuni R, White N, McDonald CR, Moiseenko V, Bartsch H, Seibert T, Farid N, Brewer J, Krishnan A, Dale A, Hattangadi-Gluth JA. Quantitative Analysis of Radiation-Induced Microstructural Injury to White Matter and Hippocampus in Brain Tumor Patients. The American Society for Radiation Oncology's (ASTRO) 57<sup>th</sup> Annual Meeting, October 18-21, 2015.
4. Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S. Trends in financial relationships between industry and individual medical oncologists in the United States between 2014-2017: a cohort study. American Society of Clinical Oncology (ASCO) Annual Meeting, May 31-June 4, 2019.
5. Marshall DC. The Radiation Oncology Alternative Payment Model: Making a Case for Integration of Principles of Palliative and Supportive Care into Radiation Oncology Clinics. AcademyHealth National Health Policy Conference, February 10-11, 2020.
6. Marshall DC, Dharmarajan K, Wei R, Tseng Y, Schuster J, Jones J, Johnstone C, Balboni T, Lo S, and Robbins J. Key factors for establishing and maintaining a successful palliative radiation oncology program: A survey of the Society for Palliative Radiation Oncology. American Radium Society Annual Meeting, May 16-20, 2020 (postponed). *Int J Radiat Oncol Biol Phys.* 108(2), supp E20-E21, October 01, 2020.

#### VOLUNTARY POSTER SCIENTIFIC PRESENTATIONS

1. Dixson AD, Megason S, Trinh L, Marshall DC, Bronner-Fraser M, Fraser S. PKC-alpha labels a subset of long-lived Rohon-Beard neurons. USC-Caltech MD/PhD Symposium, Los Angeles, CA, 2010.
2. Barnes A, Moore AA, Xu H, Mirkin M, Marshall DC, Ang A, Tallen L, Ettner SL. The effect of a Patient-Provider Educational Intervention to Reduce At-Risk Drinking on Changes in Health and Health-

Related Quality of Life among Older Adults: The Project Share Study. AcademyHealth Annual Research Meeting, Boston, MA, June 2010.

3. Marshall DC, Metzger MF, Bae HW, Zhao L, Kanim LEA, Wong P, Delamarter RB. Bone Marrow Aspirate with a Sub-effective Dose of rhBMP-2 in Spinal Fusion: A Quantitative Analysis. Orthopaedic Research Society Annual Meeting, San Francisco, CA, February 2012.
4. Woo JR, Strasner A, Jeong YB, Liss MA, Muldong M, Raheem O, Wu C, Melo-Cardenas J, Yamaguchi T, Leu H, Marshall D, Morris SR, Cacalano NA, Masuda K, Jamieson CHM, Karin M, Kulidjian AA, Kane CJ, and Jamieson CAM. Novel prostate cancer patient-derived xenograft models and mechanisms of bone metastatic castrate-resistant prostate cancer. University of California, San Diego Surgery Research Symposium, San Diego, CA, April 26-27, 2013.
5. Wu C, Strasner A, Woo JR, Muldong M, Jeong YB, Liss MA, Raheem O, Yamaguchi T, Leu H, Marshall D, Morris SR, Cacalano NA, Masuda K, Jamieson CHM, Kulidjian AA, Kane CJ, and Jamieson CAM. Novel prostate cancer patient-derived xenograft models of bone metastatic castrate-resistant prostate cancer. American Association for Cancer Research (AACR) Special Conference: Translational Impact of Model Organisms in Cancer, San Diego, CA, Nov. 5-8, 2013.
6. Hattangadi-Gluth JA, Marshall DC, Recht A, Murphy J, Sanghvi P, Fox D, and Punglia RS. Medical Malpractice in Radiation Oncology: A Population-Based Study 1985-2012. The American Society for Radiation Oncology's (ASTRO) 56<sup>th</sup> Annual Meeting, San Francisco, CA, September 14-17, 2014.
7. Jamieson C, Wu C, Strasner A, Woo JR, Muldong M, Jeong YB, Liss MA, Raheem O, Yamaguchi T, Leu H, Deborah Marshall D, Morris S, Cacalano NA, Masuda K, Jamieson CHM, Kulidjian AA, Kane CJ. Novel prostate cancer patient-derived xenograft models of bone metastatic castrate-resistant prostate cancer. [abstract]. In: Proceedings of the AACR Special Conference: The Translational Impact of Model Organisms in Cancer; Nov 5-8, 2013; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res2014;12(11 Suppl):Abstract nr A43. doi: 10.1158/1557-3125.MODORG-A43Mol Cancer Res
8. Marshall DC, Recht A, Punglia RS and Hattangadi-Gluth JA. The Nature of Malpractice Claims in Radiation Oncology from 1985-2012. American College of Radiation Oncology (ACRO) Annual Meeting, Arlington, VA, May 15-16, 2015.
9. Marshall DC, Jackson ME, and Hattangadi-Gluth JA. Distribution of industry payments to physicians certified by the American College of Radiology: Initial results from Open Payments program reports. American College of Radiology (ACR) Annual Meeting, Washington, DC, May 17-21, 2015.
10. Marshall DC, Jackson ME, and Hattangadi-Gluth JA. Disclosure of industry payments to oncologists: Early open payments data. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, May 29-June 2, 2015.
11. Jackson ME, Marshall DC, and Hattangadi-Gluth JA. Distribution of Industry Payments to Physicians: Initial Results from Open Payments (OP) Program Reports. AcademyHealth Annual Research Meeting, Minneapolis, MN, June 14-16, 2015.
12. Karunamuni R, Bartsch N, White N, Moiseenki V, Carmona R, Marshall DC, Seibert TM, McDonald C, Farid N, Krishnan A, Brewer J, Dale AM, Hattangadi JA. Dose-Dependent Cortical Thinning After Partial-Brain Radiation in Glioblastoma. The American Society for Radiation Oncology's (ASTRO) 57<sup>th</sup> Annual Meeting, October 18-21, 2015.

13. Connor M, Marshall DC, Karunamuni R, Moore KL, Pawlicki T, Mundt AJ, Hattangadi J. Food and Drug Administration (FDA) Medical Device Reports from 1991-2015: Are Radiation Oncology Devices Different? The American Society for Radiation Oncology's (ASTRO) 58<sup>th</sup> Annual Meeting, September 25-28, 2016.
14. Burkeen J, Pan T, Marshall DC, McDuff S, Gorman MK, Sanghvi P, Cheng R, McDonald C and others. Quality of Life (QoL) in Patients Undergoing Intracranial Radiation Therapy (RT). The American Society for Radiation Oncology's (ASTRO) 58<sup>th</sup> Annual Meeting, September 25-28, 2016.
15. Connor M, Karunamuni R, McDonald C, White N, Pettersson N, Moissenko V, Siebert TM, Marshall DC, and others. Multi b-value Diffusion Imaging of Radiation-Induced White Matter Damage. The American Society for Radiation Oncology's (ASTRO) 58<sup>th</sup> Annual Meeting, September 25-28, 2016.
16. Seibert T, Karunamuni R, Tringale KR, Nguyen T, Leyden K, Uttarwar V, Marshall DC, Simpson D, and others. Atrophy of Entorhinal Cortex after Radiation Therapy Associated with Memory Decline. The American Society for Radiation Oncology's (ASTRO) 59<sup>th</sup> Annual Meeting, September 24-27, 2017.
17. Tringale KR, Karunamuni R, Nguyen T, Seibert TM, Leyden K, Uttarwar V, Murzin V, Marshall DC, and others. Prospective Trial of Quantitative Neuroimaging Correlates of Verbal and Nonverbal Memory Decline. The American Society for Radiation Oncology's (ASTRO) 59<sup>th</sup> Annual Meeting, September 24-27, 2017.
18. Tringale KR, Karunamuni R, Nguyen T, Seibert TM, Leyden K, Uttarwar V, Murzin V, Marshall DC, and others. Diffusion Imaging Biomarkers of Regional White Matter Injury Correlate with Change in Executive Function and Processing Speed after Brain Radiation Therapy. The American Society for Radiation Oncology's (ASTRO) 59<sup>th</sup> Annual Meeting, September 24-27, 2017.
19. Burkeen J, Pan T, Dalia Y, Sharifzadeh Y, Marshall DC, McDonald C, Hattangadi-Gluth JA. Gender Differences in Health-Related Quality of Life (hrQOL) in Patients Undergoing Intracranial RT. The American Society for Radiation Oncology's (ASTRO) 60<sup>th</sup> Annual Meeting, October 21-24, 2018.
20. Huynh-Le MP, Tringale KR, Karunamuni R, Marshall DC, Burkeen J, Seibert TM, Nguyen T, Moiseenko V, and others. Dosimetric Predictors of Cognitive Decline in Attention and Processing Speed after Fractionated Brain Radiation Therapy. The American Society for Radiation Oncology's (ASTRO) 60<sup>th</sup> Annual Meeting, October 21-24, 2018.
21. Burkeen J, Karunamuni R, Tringale KR, Seibert TM, Nguyen T, Marshall DC, Leyden K, Gorman MK, and others. Quantitative Neuroimaging and Neurocognitive Assessments to Determine Radiation Dosing Parameters to Memory Network Structures and Associated Memory Decline. The American Society for Radiation Oncology's (ASTRO) 60<sup>th</sup> Annual Meeting, October 21-24, 2018.
22. Tringale KR, Nguyen T, Bahrami N, Marshall DC, Leyden K, Karunamuni R, Seibert TM, Gorman MK, and others. Early Diffusion Imaging Biomarkers of Prefrontal Lobe White Matter Microstructural Damage are Associated with Executive Dysfunction Following Radiation Therapy in Patients with Primary Brain Tumors: A Prospective, Longitudinal Study. The American Society for Radiation Oncology's (ASTRO) 60<sup>th</sup> Annual Meeting, October 21-24, 2018.
23. Liu B, Marshall D, Rosenzweig K, Kong J, Wisnivesky J, Sigel K. Long-Term Cardiovascular Risk Following Radiation Therapy in Lung Cancer. American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. DOI: 10.1164/ajrccm-conference.2019.199.1\_MeetingAbstracts.A7285

24. Marshall DC. Trends in Industry Payments to Radiation Oncologists from 2014-2017. European Society for Radiotherapy and Oncology (ESTRO) 38<sup>th</sup> Annual Congress, April 26-30, 2019.
25. Marshall DC, Gupta, V, Saitta A, Ghiassi-Nejad Z, Powers A, Sheu R, Lo Y, Dumane V. The Effect of Source Anisotropy on Dose Distribution and Active Length in Vaginal Brachytherapy: An Institutional Comparison of Two Afterloaders and Treatment Planning Systems. American Brachytherapy Society (ABS) Annual Meeting, June 13-15, 2019.
26. Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S. Trends in Financial Relationships Between Industry and US Radiation Oncologists from 2014-2017: A Cohort Study. The American Society for Radiation Oncology's (ASTRO) 61<sup>st</sup> Annual Meeting, IJROBP, 105(1): E466. September 1, 2019.
27. Tibbs MD, Huynh-Le MP, Reyes A, Macari AC, Karunamuni R, Tringale KR, Burkeen J, Marshall DC, McDonald C, Hattangadi-Gluth JA. Microstructural Injury to Perisylvian White Matter Predicts Language Decline after Brain Radiotherapy [RT]: Quantitative Analysis of a Prospective Trial. The American Society for Radiation Oncology's (ASTRO) 61<sup>st</sup> Annual Meeting, IJROBP, 105 (1): S79-S80. September 1, 2019.
28. Tibbs MD, Huynh-Le MP, Reyes AC, Macari AC, Karunamuni R, Tringale KR, Burkeen J, Marshall DC, McDonald C, Hattangadi-Gluth JA. Longitudinal Analysis of Depression and Anxiety Symptoms as Independent Predictors of Neurocognitive Function: Prospective Trial of Brain Tumor Patients Receiving Radiotherapy [RT]. The American Society for Radiation Oncology's (ASTRO) 61<sup>st</sup> Annual Meeting, IJROBP, 105 (1): S80. September 1, 2019.
29. Cha E, Gillespie EF, Ru M, Lapen K, Sharma S, Mun S, Calhon O, Marshall DC. Factors influencing patient experience ratings in radiation oncology. American College of Radiation Oncology (ACRO): The Radiation Oncology Summit, ACRO 2020 Annual Meeting, February 27-29, 2020.
30. Lehrer E, Yashar C, Rosenzweig K, Bakst R, Marshall DC. Trends in Medicare billing by specialty for electronic skin brachytherapy from 2012-2017. American Radium Society, May 16-19, 2020 (postponed).
31. Mutetwa T, Marshall D, Saleem Rehmani S, Sigel Keith. Lung cancer chemotherapy and radiotherapy toxicity in patients with HIV. 2020 ASCO Annual Meeting. Journal of Clinical Oncology 38(15\_suppl):e13616-e13616. DOI: 10.1200/JCO.2020.38.15\_suppl.e13616
32. Marshall DC, Ghiassi-Nejad Z, Powers A, Argiriadi P, Reidenberg J, Ru M, Dumane V, Buckstein M, Goodman K, Schnur J, Rosenstein B. A dosimetric comparison of a novel clitoris-sparing intensity modulated radiotherapy (IMRT) approach vs. standard IMRT for treatment of female patients with anal cancer. The American Society for Radiation Oncology's (ASTRO) 62<sup>nd</sup> Annual Meeting, 2020.
33. Marshall DC, Green S, Starrs C, Montgomery G, Minassian K, Wunder B, Force J, Schnur J. A trauma-informed Sensitive Practice Tool to enhance quality of care for breast radiotherapy patients. The American Society for Radiation Oncology's (ASTRO) 62<sup>nd</sup> Annual Meeting, 2020.
34. Hardy Abeloos C, Sigel K, Rosenstein B, Busckstein M, and Marshall DC. Subsequent anal malignancies in patients with prostate adenocarcinoma treated with brachytherapy or external beam radiation compared with surgery. The American Society for Radiation Oncology's (ASTRO) 62<sup>nd</sup> Annual Meeting, 2020.

35. Sigel K, Rodriguez-Barradas M, Stone K, Goetz M, Brown S, Bedimo R, Shebl F, Crothers K, Marshall D, Park LS. Treatment toxicity for lung cancer patients with and without HIV infection. Conference on Retroviruses and Opportunistic Infections (CROI), March 2021.
36. Morgan O, Powers A, Ghiasi-Nejad Z, Reidenberg JS, Argiriadi P, Buckstein M, Goodman KA, Schnur JB, Rosenstein BS, and Marshall DC. Dosimetric Comparison of a Novel Bulboclitoris-Sparing Intensity Modulated Radiotherapy (IMRT) Approach vs. Standard IMRT for Treatment of Female Patients with Low Rectal Cancer. The Scientific Network on Female Sexual Health and Cancer, 2021 Virtual Scientific Session, April 2021.
37. Bloom JR, Marshall DC, Rodriguez-Russo C, Martin EJ, Jones JA, Dharmarajan KV. Prognostic disclosure: A scoping review on communication guidelines and their application in oncology. *J Clin Oncol* 39, 2021 (suppl 15; abstr e24107). 10.1200/JCO.2021.39.15\_suppl.e24107. ASCO 2021.
38. Marshall DC, Kerns S, West C, Rosenstein B. A comparison of radiation toxicity outcomes in patients with and without autoimmune diagnoses on the REQUITE study. ASTRO, 2021.
39. Bloom J, Marshall DC, Sheu R, Liu J, Gupta V, Bakst R, Sharma S. The impact of the COVID-19 pandemic on a single institution's head and neck radiation therapy population in New York City. ASTRO 2021.
40. Morgan O, Duenas-Lopez M, Caban-Martinez AJ, Marshall D, Schnur J. A Systemic Literature Review Comparing Plastic versus Silicone Dilators: Efficacy, Cost & Patient Preferences. Accepted for Presentation at American Psychosocial Oncology Society 2022 Conference.
41. Morgan O, Schnur J, Caban-Martinez A, Duenas-Lopez M, Huang M, Portelance L, Marshall D. Perspectives on Sexual Health Among Women who Underwent Pelvic Radiation Therapy: A Qualitative Analysis Accepted at International Society for the Study of Women's Sexual Health (ISSWSH) 2022 Conference.
42. Hsieh K, et al. Factors associated with U.S. hospital payer-specific negotiated mammography charges. 2022 ASCO Annual Meeting.
42. Hsieh K, et al. Factors Associated With Hospital-Negotiated Prices Of Tandem & Ovoids In The U.S. In 2021. American Brachytherapy Society's 2022 Annual Meeting.
43. Rodriguez N, et al. 7 Tesla MRI Evaluation of Adenoid Cystic Carcinoma Perineural Spread versus 3T and 1.5 T MRI- Does increased Field Strength Affect Radiation Treatment Planning? 2022 Annual Meeting of the American Society of Head and Neck Radiology.
44. Downes M, et al. The Lesser Whole "CN IX" Yards - Clinically Important CN IX Lesser Petrosal Nerve Connections on 7 Tesla MRI versus Lower Field Strengths. 2022 Annual Meeting of the American Society of Head and Neck Radiology.
45. Greenwald et al. The Bulboclitoral Erectile Tissues: A Previously Unacknowledged Organ at Risk During Radiotherapy. ISSM/SMSNA Joint Scientific Meeting 2022, Miami, FL, USA.
46. Downes et al. Potential improvement in female sexual outcomes in rectal cancer – comparison of IMRT vs. 3D-CRT to spare erectile and other sexual structures. 8th Conference of the Scientific Network on Female Sexual Health and Cancer, Yale University, New Haven, Connecticut, November 17-18, 2022

47. Wang J, et al. Evaluating imaging reproducibility of portable ultrasound devices with histogram analysis: a phantom study. *Ultrasonic Imaging and Tomography*, part of SPIE Medical Imaging.
48. Cohen E, et al. Hydrogel Technologies to Prevent Vaginal Stenosis after Pelvic Radiotherapy. *AIChE Annual Meeting*.
49. Langan M, Marshall DC, Shrivastava R, Delman B, and Balchandani P. Quantitative assessment of secondary white matter injury and volumetric changes in hypothalamic subnuclei by Pituitary tumors utilizing 7-Tesla MRI. *ISMRM 2023*, Toronto, ON Canada.
50. McWilliam A, et al. Do patients with lung cancer and a genetic risk for rheumatoid arthritis have increased toxicity? *ESTRO 2023*, Vienna, Austria.
51. Dickstein D, et al. Association Between Treatment Choice and Sexual Outcomes in Gay and Bisexual Men with Early-Stage Prostate Cancer. *American Radium Society*, 2023, Maui, HI USA.
52. Bloom J, Chubak B, Marshall DC, Hotca-Cho A, Dickstein D, Hsieh K, Ghiassi-Nejad Z, Gupta V, Buckstein M, Chadha M, Goodman K. Combination Therapy for Sexual Rehabilitation after Pelvic Radiation: A Prospective Feasibility Trial. *American Radium Society*, 2023, Maui HI USA.
53. Rodriguez-Russo C, et al. An Atlas for Contour Delineation of Genital Anatomy in Patients with Gender Incongruence Who Have Undergone Feminizing Gender-Affirming Genital Surgery. *American Radium Society*, 2023, Maui, HI, USA.
54. Muallem J, Hasan S, Marshall D, Fox J, Bakst R, Chhabra A, Simone C, Choi I. Practice Patterns and Disparities of Fractionation Schemes for Post-mastectomy Comprehensive Nodal Irradiation. *ASTRO 2023*, San Diego, CA.
55. Rodriguez-Russo C, Edwards K, Ijaz M, Michel R, Baruwa A, Minassian K, Vavasis C, Lynch K, Lawshe E, Smith K, Marshall D, Rosenzweig K, Goodman K. Long-term Outcomes of Multidisciplinary Radiation Oncology Equity and Inclusion Committee Programming at an Academic Health System. *ASTRO 2023*, San Diego, CA.
56. Marshall D, Shim A, Chen C, Lin H, Yu F, Argiriadi P, Choi I, Chhabra A, Simone C. A dosimetric assessment of sexual organ sparing proton radiotherapy in female pelvic cancer patients. *ASTRO 2023*, San Diego, CA.